GT307 injection

BIOLOGICAL4 trials

Sponsors

Grit Biotechnology

Conditions

AdultAdvanced Solid TumorsSolid Tumor, Adult

Unknown Phase

Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours

RecruitingNCT06397963

Grit BiotechnologySolid Tumor, Adult

Start: 2024-04-18End: 2027-04-18Target: 18Updated: 2026-01-26

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours

RecruitingNCT06453057

Grit BiotechnologyAdult

Start: 2024-07-04End: 2027-06-06Target: 18Updated: 2026-04-14

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer

RecruitingNCT06819280

Grit BiotechnologyAdult

Start: 2024-06-28End: 2027-05-27Target: 18Updated: 2026-04-14

A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors

WithdrawnNCT07534813

Grit BiotechnologyAdvanced Solid Tumors

Start: 2026-04-30End: 2028-05-31Updated: 2026-06-09

Related Papers

Evaluating the safety and efficacy of CRISPR/AaCas12b <sup>Max</sup> -modified tumor infiltrating lymphocytes (GT300) as monotherapy in advanced solid tumors.

Journal of Clinical Oncology2025-05-281 citations